石四藥集團有限公司
## SSY Group Limited

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2005)**

**VOLUNTARY ANNOUNCEMENT**
**UPDATE ON PRODUCT DEVELOPMENT**

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group's Deferasirox has obtained the approval for registration from the National Medical Products Administration of China (the "NMPA") to become a bulk drug for the preparations on the market. Deferasirox is mainly used in patients with iron accumulation due to the need for long-term blood transfusions (such as thalassemia or other rare anemias patients).

In addition, the Board is also pleased to announce that the Group has obtained the approval for drug production and registration for Esmolol Hydrochloride Injection (10ml:0.1g) from the NMPA, being under type 3 chemical drug and regarded as passing the consistency evaluation. Esmolol Hydrochloride Injection is mainly used in supraventricular tachycardia or non-compensatory sinus tachycardia, intraoperative and postoperative tachycardia and/or hypertension.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
**Chow Hing Yeung**
*Executive Director and Company Secretary*

Hong Kong, 28 June 2024

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.*